BROOMFIELD, Colo., March 25 /PRNewswire/ -- Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system (CNS) disorders, today announced that the company will be participating at two upcoming healthcare investor conferences.
Dr. Steve Orndorff, Founder, President and CEO, will speak at the 2nd Annual BIO Venture Conference on April 1 at 10:15 a.m. EDT at the Sheraton Boston Hotel in Boston, MA. On April 9 at 11:30 a.m. PDT, he will present at the C21 BioVentures Conference at the Meritage Resort in Napa Valley, CA.
In early March, the company launched Axona(TM), a medical food available only by prescription for mild-to-moderate Alzheimer's disease. Dr. Orndorff will provide an overview of Accera and its technology pipeline and also provide an update on the successful nationwide launch of Axona.
About Accera, Inc.
Accera, Inc., a privately held biotechnology company, discovers and develops product breakthroughs in treating central nervous system disorders. Accera's novel therapeutic approaches positively impact patients with neurodegenerative disorders, who are in need of effective, well-tolerated treatments. Through its proprietary scientific platform, Accera is developing therapies that address metabolic deficiencies by providing an alternative energy source to the brain.
Axona is a first-in-class medical food for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease. Dispensed by prescription, Axona targets the metabolic deficiencies and imbalances associated with Alzheimer's disease by providing an alternative energy source for brain cells. With simple administration and once-a-day convenience, Axona is complementary to current Alzheimer's disease therapies.
Contacts: Media: Investors: Gregory Tiberend Cecelia Heer Richard Lewis Communications, Inc. Richard Lewis Communications, Inc. Ph: (212) 827-0020 Ph: (212) 827-0020 firstname.lastname@example.org email@example.com
|SOURCE Accera, Inc.|
Copyright©2009 PR Newswire.
All rights reserved